NCT04330248View on ClinicalTrials.gov

A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

June 14, 2022

Study Completion Date

June 14, 2022

Conditions
Healthy
Interventions
DRUG

Erdafitinib

Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.

DRUG

Carbamazepine

Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT04330248 - A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants | Biotech Hunter | Biotech Hunter